Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition ...

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...